Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: j bayer who wrote (7156)	4/16/1998 4:17:00 PM
From: Colby	Respond to of 23519

J, I agree with most everything you have said, but as I said in the post to Bruce, I think there will be a lot of cases where PFE doesn't work (moderate to severe ED). What product will these people choose? My money says VVUS. Being #2 ain' that bad, Colby

To: j bayer who wrote (7156)	4/16/1998 5:48:00 PM
From: VLAD	Read Replies (1) \| Respond to of 23519

j bayer, There will be patients using both products--Viagra for "planed events" and MUSE or the needle for spontaneous events. Script #'s for last week showed refills up 3% and new scripts down 16% The increase in refills tells me that MUSE does have a loyal following The decrease in new scripts is no doubt the Viagra effect. It will be very interesting to see how the numbers change as each week passes. I expect a drop in new scripts for about 3-4 weeks and then an increase to preViagra levels in another 3-4 weeks. After a few months we will see many new MUSE patients that either could not tolerate or take Viagra or who it did not work on.